Newbury Pharmaceuticals

Prenumeration

Kalender

	Est. tid*
2026-01-14	N/A	Årsstämma
2026-01-14	08:00	Kvartalsrapport 2026-Q1
2025-10-29	11:20	Bokslutskommuniké 2025
2025-07-09	-	Kvartalsrapport 2025-Q3
2025-04-09	-	Kvartalsrapport 2025-Q2
2025-01-24	-	Kvartalsrapport 2025-Q1
2025-01-16	-	X-dag ordinarie utdelning NEWBRY 0.00 SEK
2025-01-15	-	Årsstämma
2024-10-23	-	Bokslutskommuniké 2024
2024-07-31	-	Extra Bolagsstämma 2024
2024-07-10	-	Kvartalsrapport 2024-Q3
2024-04-10	-	Kvartalsrapport 2024-Q2
2024-01-11	-	X-dag ordinarie utdelning NEWBRY 0.00 SEK
2024-01-10	-	Årsstämma
2024-01-10	-	Kvartalsrapport 2024-Q1
2023-10-11	-	Bokslutskommuniké 2023
2023-07-14	-	Kvartalsrapport 2023-Q3
2023-04-12	-	Kvartalsrapport 2023-Q2
2023-01-12	-	X-dag ordinarie utdelning NEWBRY 0.00 SEK
2023-01-11	-	Årsstämma
2023-01-11	-	Kvartalsrapport 2023-Q1
2022-10-13	-	Bokslutskommuniké 2022
2022-07-06	-	Kvartalsrapport 2022-Q3
2022-04-13	-	Kvartalsrapport 2022-Q2

Beskrivning

Land	Sverige
Lista	First North Stockholm
Sektor	Hälsovård
Industri	Läkemedel & Handel

Newbury Pharmaceuticals är verksamt inom läkemedelsbranschen. Bolaget utvecklar en pipeline av egenutvecklade och licensierade produkter med fokus på specialläkemedel inom områden som onkologi, sällsynta sjukdomar och neurologi. Bolaget bedriver sin verksamhet inom den skandinaviska marknaden. Newbury Pharmaceuticals grundades 2020 och har sitt huvudkontor i Lund.

Filter

År

Typ

Språk

Rensa

2025-07-09 08:00:00 Newbury Pharmaceuticals interim report September 2024 – May 2025 2,82 SEK | -7,24% | 1,62 MSEK

2025-04-28 09:21:00 Newbury Pharmaceuticals carries out a directed share issue of approximately SEK 16 million and extends the existing SEK 15 million loan agreement 3,06 SEK | -6,99%

2025-04-16 13:30:00 Newbury Pharmaceuticals Secures Generic Approval for Pazopanib Newbury 3,36 SEK | -0,30%

2025-04-09 08:00:00 Newbury Pharmaceuticals interim report September 2024 – February 2025 3,34 SEK | -1,18%

2025-03-19 11:00:00 Newbury Pharmaceuticals expands its portfolio with four new products 3,38 SEK | +1,20%

2025-03-14 08:30:00 Newbury Pharmaceuticals Secures Approval for Macitentan film-coated tablets 3,34 SEK | +2,45%

2025-01-24 10:00:00 Newbury Pharmaceuticals Secures Generic Approval for Pomalidomide capsules 3,48 SEK | -2,25%

2025-01-24 08:00:00 Newbury Pharmaceuticals interim report September 2024 – November 2024 3,48 SEK | -2,25%

2025-01-22 09:00:00 Newbury Pharmaceuticals Secures Generic Approval for Bosutinib tablets 3,54 SEK | +0,57%

2025-01-15 14:00:00 Newbury Pharmaceuticals Secures Generic Approval for Azelastine + Fluticasone nasal spray 3,46 SEK | +1,76%

2025-01-15 11:23:00 ANNUAL GENERAL MEETING OF SHAREHOLDERS IN NEWBURY PHARMACEUTICALS AB 3,46 SEK | +1,76%

2024-12-11 19:30:00 Newbury Pharmaceuticals publishes its annual report for 2023/2024 3,62 SEK | +3,43%

2024-12-11 09:30:00 Kallelse till årsstämma i Newbury Pharmaceuticals AB 3,50 SEK | -3,31%

2024-10-28 10:00:00 Newbury Pharmaceuticals Secures Generic Approval for Buspiron 4,00 SEK | +3,09%

2024-10-23 11:15:00 Newbury Pharmaceuticals year-end report September 2023 – August 2024 3,78 SEK | -4,55%

2024-09-30 09:00:00 Newbury Pharmaceuticals AB has agreed to extend the existing 15 MSEK loan agreement. 3,78 SEK | +3,28%

2024-09-27 15:56:00 Strong Quarterly Sales Announcement from Newbury Pharmaceuticals 3,66 SEK | +10,91%

2024-09-23 13:00:00 Newbury Pharmaceuticals Secures Approval for Varenicline in Sweden 3,18 SEK | +5,30%

2024-09-13 11:30:00 Regulatory Filing for Teduglutide 3,26 SEK | +5,16%

2024-07-31 10:04:00 Extraordinary general meeting in Newbury Pharmaceuticals AB (publ) 3,70 SEK | +5,11%

2024-07-12 09:30:00 NOTICE OF EXTRAORDINARY GENERAL MEETING IN NEWBURY PHARMACEUTICALS AB 3,30 SEK | -2,37%

2024-07-10 08:00:00 Newbury Pharmaceuticals interim report September 2023 – May 2024 3,26 SEK | -6,86%

2024-06-20 13:00:00 Newbury Pharmaceuticals Secures Generic Approval for Liraglutide Pre-Filled Pen 3,46 SEK | +8,81%

2024-06-18 08:45:00 Newbury Pharmaceuticals is strengthening its portfolio with Dalbavancin Powder 3,28 SEK | +1,86%

2024-04-10 08:00:00 Newbury Pharmaceuticals interim report September 2023 – February 2024 3,41 SEK | -2,29%

2024-03-04 08:15:00 Newbury Pharmaceuticals carries out a directed share issue of approximately SEK 19 million 4,39 SEK | -0,90%

2024-02-22 08:30:00 Newbury Pharmaceuticals receives international sales order valued at 8.8 million SEK 4,39 SEK | +2,33%

2024-01-17 10:00:00 Nintedanib Newbury approved by the Swedish Health Authorities 3,75 SEK | +1,63%

2024-01-10 11:20:00 ANNUAL GENERAL MEETING OF SHAREHOLDERS IN NEWBURY PHARMACEUTICALS AB 3,67 SEK | +16,51%

2024-01-10 08:00:00 Newbury Pharmaceuticals interim report September 2023 – November 2023 3,67 SEK | +16,51%

2023-12-13 23:00:00 Newbury Pharmaceuticals publishes its annual report for 2022/2023 3,79 SEK | +1,88%

2023-12-08 13:00:00 Kallelse till årsstämma i Newbury Pharmaceuticals AB 3,64 SEK | +3,41%

2023-10-20 08:00:00 Newbury Pharmaceuticals is strengthening its portfolio with Melatonin Extended Release 2 mg 3,03 SEK | -0,66%

2023-10-11 08:00:00 Newbury Pharmaceuticals year-end report September 2022 – August 2023 3,32 SEK | +1,53%

2023-10-06 13:00:00 Newbury Pharmaceuticals has entered into a partnership granting access to 6 registered products. 3,15 SEK | +3,62%

2023-09-22 10:00:00 Newbury Pharmaceuticals is strengthening its portfolio with Levodopa/Benserazide 3,91 SEK | +3,71%

2023-09-18 14:00:00 Newbury Pharmaceuticals AB has successfully signed a 15 MSEK loan agreement 3,91 SEK | +1,56%

2023-08-23 08:00:00 Newbury gains access to the Nordic hospital market with a new strategic partnership for prescription medicine 3,95 SEK | 0,00%

2023-07-19 11:30:00 Desmopressin Newbury approved by the Swedish Health Authorities 3,23 SEK | +5,90%

2023-06-16 09:42:00 Newbury Pharmaceuticals sets financial goals for 2024 and 2028 4,08 SEK | -0,49%

2023-06-14 08:00:00 Newbury Pharmaceuticals interim report September 2022 – May 2023 3,57 SEK | +0,56%

2023-06-13 17:40:00 Newbury Pharmaceuticals brings forward interim report for third quarter 2022/2023 from July 7 to June 14 3,57 SEK | +0,56%

2023-05-25 13:00:00 Newbury to present at Redeye Growth Day 2023 5,22 SEK | -3,33%

2023-05-12 08:30:00 Pirfenidone Newbury approved by the Norwegian Health Authorities 5,48 SEK | +1,48%

2023-05-02 11:00:00 Solifenacin/Tamsulosin Newbury approved by the Norwegian Health Authorities 5,56 SEK | -2,46%

2023-04-12 08:00:00 Newbury Pharmaceuticals interim report September 2022 – February 2023 5,68 SEK | -12,88%

2023-03-24 11:45:00 Lapatinib Newbury approved by the Swedish Health Authorities 6,13 SEK | +6,07%

2023-03-06 14:30:00 Dimethyl Fumarate Newbury approved by the Swedish Health Authorities 6,00 SEK | -3,23%

Visa fler

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Newbury Pharmaceuticals

Prenumeration

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden